Hypertensive disorders of pregnancy and cardiovascular disease are intimately related. They share many of the same risk factors, mechanisms for disease, and biological markers. For this study, researchers measured tiny pieces of RNA in a pregnant woman’s blood (called microRNAs) during early pregnancy. Researchers asked if microRNAs that are linked to cardiovascular disease in non-pregnant people, could help predict HELLP syndrome (a severe variant of preeclampsia that affects the liver, red blood cells, and platelets).
The study results show good prediction performance for six microRNAs measured in early pregnancy (10-13 weeks gestation) to predict HELLP syndrome later in pregnancy. When microRNA results were combined with HELLP syndrome risk factors (like age, BMI, history of HELLP syndrome, etc.), about 90% of HELLP syndrome cases were predicted (with a 10% false positive rate). This study is a novel approach that combines clinical characteristics and microRNA information in early pregnancy to predict HELLP syndrome. The study was small and should be replicated in a larger study with more patients to support these findings.
More information on HELLP syndrome.
Link: https://www.mdpi.com/1422-0067/24/6/5177
Citation: Hromadnikova, I.; Kotlabova, K.; Krofta, L. First-Trimester Screening for HELLP Syndrome—Prediction Model Based on MicroRNA Biomarkers and Maternal Clinical Characteristics. Int. J. Mol. Sci. 2023, 24, 5177. https://doi.org/10.3390/ijms24065177
Each quarter, our team of science writers reviews the most current research studies related to hypertensive disorders of pregnancy and summarizes those studies of greatest interest and potential impact to our community, including research studies related to risk assessment, diagnosis, prevention, and treatment. Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible and to our Patient Advisory Council, who reviews these materials from the patient perspective.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may b...
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...